Changes in Non-Deamidated versus Deamidated Epitope Targeting and Disease Prediction during the Antibody Response to Gliadin and Transglutaminase of Infants at Risk for Celiac Disease
Open Access
- 24 February 2022
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (5) , 2498
Abstract
Celiac disease (CeD) is a conditional autoimmune disorder with T cell-mediated immune response to gluten coupled with antibody production to gliadin and the self-protein tissue transglutaminase (TG2). TG2 contributes to the CeD pathomechanism by deamidating gliadin, thereby generating more immunogenic peptides. Anti-gliadin antibodies may appear before the autoantibody production. The scope of this study was to dissect these early antibody responses by investigating serum samples collected during the PreventCD prospective double-blind study, where infants with high CeD risk were randomized to 200 mg daily gluten intake or placebo from 4 to 6 months of age, followed by frequent blood testing on regular gluten consumption in both groups. After primary gluten intake, children with or without later CeD produced IgA and IgG antibodies which preferentially recognized non-deamidated gliadin peptides. At CeD development with anti-TG2 seroconversion, there was a significant increase in the antibody reaction toward deamidated gliadin peptides (DGP), with maturation in the binding strength for the PEQPFP gamma-gliadin core peptide. The earliest produced autoantibodies targeted TG2’s celiac epitope 2. Our results reveal a qualitative change in the gliadin-directed humoral immune response at the time when anti-TG2 antibodies appear, but anti-DGP antibodies in the absence of anti-TG2 antibodies are not disease-predictive.Keywords
Funding Information
- Nemzeti Kutatási és Technológiai Hivatal (NKFI 120392)
- European Centre for the Development of Vocational Training (EFOP-3.6.1-16-2016-00022)
- Interreg Danube CD SKILLS project (DTP3-571-1.2 CD SKILLS)
- FP6 (FP6-2005-FOOD-4B-36383–PREVENTCD)
This publication has 36 references indexed in Scilit:
- Transglutaminase 2–Specific Autoantibodies in Celiac Disease Target Clustered, N-Terminal Epitopes Not Displayed on the Surface of CellsThe Journal of Immunology, 2013
- Triggers and drivers of autoimmunity: lessons from coeliac diseaseNature Reviews Immunology, 2013
- Gliadin Peptides Induce Tissue Transglutaminase Activation and ER-Stress through Ca2+ Mobilization in Caco-2 CellsPLOS ONE, 2012
- Nomenclature and listing of celiac disease relevant gluten T-cell epitopes restricted by HLA-DQ moleculesImmunogenetics, 2012
- A single conformational transglutaminase 2 epitope contributed by three domains is critical for celiac antibody binding and effectsProceedings of the National Academy of Sciences of the United States of America, 2011
- Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac diseaseNature Genetics, 2011
- Identification and Analysis of Multivalent Proteolytically Resistant Peptides from Gluten: Implications for Celiac SprueJournal of Proteome Research, 2005
- In vivo targeting of intestinal and extraintestinal transglutaminase 2 by coeliac autoantibodiesGut, 2004
- Specificity of Tissue Transglutaminase Explains Cereal Toxicity in Celiac DiseaseJournal of Experimental Medicine, 2002
- Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatmentThe FASEB Journal, 2002